A global, innovation-driven pharmaceutical company Glenmark Pharmaceuticals Limited and Canadian pharmaceutical company SaNOtize Research & Development Corporation announced launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray® in India for the treatment of adult patients with COVID-19 who have high risk of progression of the disease. Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS as part of the accelerated approval process.
FabiSpray®, Nitric Oxide Nasal Spray is designed to kill the COVID-19 virus in the upper airways. Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94% in 24 hours and 99% in 48 hours. SaNOtize showed NONS was a safe and effective antiviral treatment of SARS CoV-2. NONS has been tested in healthy volunteers and patients as part of Canada and UK clinical trials.
The Senior VP & Head of Clinical Development of Glenmark Pharmaceuticals Ltd. Dr. Monika Tandon said, “The results from this Phase 3, double blind, placebo controlled trial are encouraging. Demonstration of reduction in the viral load has significant positive impact from a patient and community perspective.”
